Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Head-to-head comparison of BPC-157 and Thymosin Alpha-1 — mechanism, side effects, legal status, and pricing.
BPC-157 is a synthetic pentadecapeptide (sequence GEPPPGKPADDAGLV) derived from a 15-amino-acid fragment of body protection compound (BPC), a protein isolated from human gastric juice. It is research-only, not approved by the FDA or any major regulator for human use, and almost all published evidence comes from rodent models.
Thymosin Alpha-1 (Tα1) is a 28-amino-acid acetylated peptide (Ac-SDAAVDTSSEITTKDLKEKKEVVEEAEN) corresponding to the N-terminus of prothymosin α. Marketed as Zadaxin / thymalfasin and approved in 35+ countries for chronic hepatitis B/C and as an immune adjuvant, but NOT FDA-approved in the US — Phase 3 HCV trials ended without approval. Outside the US it is one of the most clinically validated immune-modulating peptides.
BPC-157
Thymosin Alpha-1
Category
Legal Status
Mechanism
Half-life
Side Effects
COA-verified vendors · trust score ≥70 required · single-vial price — bulk/bundle deals may be lower
BPC-157
Thymosin Alpha-1
COA corpus from Disclosed Labs — independently tested batches only.
BPC-157
334
COAs
99.3%
Avg purity
16
Labs
Thymosin Alpha-1
69
COAs
99.6%
Avg purity
12
Labs
BPC-157 is among peptides under FDA review for the Category 1 (503A) list; if added, it would require a prescription to be compounded by registered 503A/503B pharmacies — not yet authorized. Thymosin Alpha-1 remains research-only. In April 2026 the FDA removed 12 peptides from Category 2, which does not place them on the Category 1 list or authorize compounding. The FDA's Pharmacy Compounding Advisory Committee is advisory and meets July 23–24, 2026 to review nominations and make recommendations to the FDA.
Extensive rodent data from the Sikiric group and others report accelerated healing of tendon, ligament, muscle, and gastrointestinal injury, plus cytoprotective effects in models of NSAID and alcohol damage (PMID 21548867, 30915550). Preclinical tendon studies demonstrate enhanced growth hormone receptor expression in fibroblasts (PMID 25415472) and promote tendon outgrowth, cell survival, and cell migration (PMID 21030672). Published human clinical evidence is limited; an early oral formulation (PL 14736) was explored for inflammatory bowel disease but has not progressed to approval. No peer-reviewed trial validates the injectable doses (200–500 mcg) commonly used on the grey market, and pharmacokinetics and long-term safety in humans are not well characterized.
Key references
Thymosin alpha-1 has been studied in 90+ clinical trials. A meta-analysis by Yang et al. (Antiviral Research 2008, PMID 18078676) in chronic hepatitis B found antiviral efficacy comparable to interferon-alpha. Tuthill, Rios & McBeath (Ann N Y Acad Sci 2010, PMID 20536460) reviewed the global Zadaxin program across HBV, HCV, melanoma, HCC, and vaccine adjuvancy. Romani et al. (Blood 2006, PMID 16741252) established the TLR9 / IDO dendritic-cell mechanism that underlies Ta1's dual pro-inflammatory / tolerogenic effects. During the COVID-19 pandemic, Liu et al. (Clin Infect Dis 2020, PMID 32442287) reported reduced mortality (11.11% vs 30.00%, p=0.044) in severe lymphopenic COVID-19 patients via restoration of exhausted T cells. A 2024 systematic review by Dinetz & Lee (Altern Ther Health Med, PMID 38308608) covering 30+ trials and 11,000+ subjects concluded Ta1 is a well-tolerated and effective immune modulator, and argued the FDA's 2023 restriction appeared unfounded given the clinical evidence. US regulatory status: NOT FDA-approved; removed from 503A Category 2 in September 2024 after nominator withdrawal; PCAC voted AGAINST inclusion on the 503A Bulks List on December 4, 2024.
BPC-157 (Recovery) and Thymosin Alpha-1 (Immune) are in different categories and target different biological pathways. This is a common pattern in multi-compound research protocols. Researchers should monitor the biomarkers from both profiles and watch for interactions listed in each compound’s contraindications. Consult a licensed healthcare provider before combining any research compounds.
This platform provides informational tools only, not medical advice. This comparison is for educational purposes only. Consult a licensed provider.
Contraindications
Lab Testing
Key references
Disclosed Labs